AFERRIX is an innovative leader in the development of novel tools for diagnosis and monitoring of toxic iron and iron overload. Aferrix has developed a method and tool for the detection and quantification of iron overload in body fluids, monitoring the response to drug treatment.

THE MARKET

• Simple detection method for toxic iron
• Quick results within 2 hours
• Cost effective
• Very reliable
• Available in a kit format (research use only)

THE TECHNOLOGY

Free iron catalyzes the production of Reactive Oxygen Species (ROS) - free radicals, which cause damage to tissues such as the heart and liver. The company has developed several methods that quantify different forms of toxic iron in serum that are not detected by conventional tests.

TEAM

Dr. Nir Navot - CEO
Prof. Ioav Cabantchik, Founder & Entrepreneur
Dr. William Breuer, Founder & Entrepreneur

STATUS

AFERRIX is sourcing its product development and commercialization capabilities from Pronto Diagnostics Ltd., a leading provider of molecular diagnostic products and services, with extensive
knowledge, experience, and R&D capabilities in SNP-based analysis of genetic variations.

Aferrix provides iron-testing services to scientists who specialize in iron overload or require such measurements for their research, and to pharmaceutical companies that are developing iron chelators.

CONTACT
Tel: 972-8-9316172

Mob: 972-52-8934666

Fax: 972-8-9316173